Boost For Oral SERDs As Menarini/Radius’ Orserdu Becomes First Approved For Breast Cancer

Following US FDA Approval

 
• By Ayisha Sharma

The firms’ Orserdu has won a US thumbs up for the treatment of ESR1-mutated advanced or metastatic breast cancer, marking a positive breakthrough for the challenging SERD drug class.  

Pair of hands on the red ground of a race track, with a white number one painted on it
Menarini And Radius Have Won The Race For The First Oral SERD • Source: Shutterstock

More from New Products

More from Scrip